Silvere D Zaongo¹* and Dieudonne Ouattara²

¹Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China
²Centre de Recherche Clinique De Nanoro, Burkina Faso

*Corresponding Author: Silvere D Zaongo, Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.

Received: November 26, 2021; Published: December 07, 2021

In December 2019, cases of the third zoonotic human coronavirus epidemic were reported in China. They triggered the curiosity of local medical officers who-in the absence of evidence showing the presence of typical pathogens-had collected lower respiratory tract samples to conduct a sharp sequencing analysis revealing (in January 2020) the presence of a novel coronavirus named SARS-CoV-2 [1]. Similarly, to severe acute respiratory syndrome coronavirus (SARS-CoV) [2-4] and Middle East respiratory syndrome coronavirus (MERS-CoV) [5,6]. SARS-CoV-2 viral pneumonia is associated with symptoms such as fever, difficulty breathing, and bilateral lung infiltration in the most severe cases [7]. SARS-CoV and MERS-CoV have caused more than 10,000 cumulative cases in the past two decades, with mortality rates of 10% for SARS-CoV and 37% for MERS-CoV [8,9]. At the time of revision of this editorial (November 26, 2021), it was established that SARS-CoV-2 alone caused more than 260,200,000 and 5,100,000 cumulative cases and deaths, respectively [10].

Keywords: COVID-19; SARS-CoV; MERS-CoV; SARS-CoV-2

References

1. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet10223 (2020): 497-506.
2. Ksiazek TG., et al. “A novel coronavirus associated with severe acute respiratory syndrome”. The New England Journal of Medicine20 (2003): 1953-1966.
3. Kuiken T., et al. “Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome”. Lancet9380 (2003): 263-270.
4. Drosten C., et al. “Identification of a novel coronavirus in patients with severe acute respiratory syndrome”. The New England Journal of Medicine20 (2003): 1967-1976.
5. de Groot RJ., et al. “Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group”. Journal of Virology14 (2013): 7790-7792.
6. Zaki AM., et al. “Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia”. The New England Journal of Medicine19 (2012): 1814-1820.
7. Gralinski LE, Menachery VD. “Return of the Coronavirus: 2019-nCoV”. Viruses2 (2020): 135.
8. World Health Organization, 2015. “Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003” (2003).
9. World Health Organization. “Middle East respiratory syndrome coronavirus (MERS-CoV)” (2019).
10. “COVID-19 coronavirus outbreak” (2020).
11. National Conference of State Legislatures, 2020. “President Trump declares state of emergency for COVID-19” (2020).
12. Jia Z., et al. “In depth: How the US missed its window for taming the covid-19 virus” (2020).
13. Kahn N. “New virus discovered by Chinese scientists investigating pneumonia outbreak”. Wall Street Journal (2020).
14. Cheng VC., et al. “Clinical management and infection control of SARS: lessons learned”. Antiviral Research2 (2013): 407-419.
15. Li W., et al. “Bats are natural reservoirs of SARS-like coronaviruses”. Science 5748 (2005): 676-679.
16. Ge XY., et al. “Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor”. Nature 7477 (2013): 535-538.
17. Yang L., et al. “Novel SARS-like betacoronaviruses in bats, China, 2011”. Emerging Infectious Diseases 6 (20013): 989-991.
18. Hu B., et al. “Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus”. PLoS Pathogen11 (2017): e1006698.
19. Menachery VD., et al. “A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence”. Nature Medicine12 (2015): 1508-1513.
20. Menachery VD., et al. “SARS-like WIV1-CoV poised for human emergence”. Proceedings of the National Academy of Sciences of the United States of America11 (2016): 3048-3053.
21. Wang N., et al. “Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China”. Virologica Sinica1 (2018): 104-107.
22. Zhou P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature 7798 (2020): 270-273.
23. World Health Organization. “Novel coronavirus-Japan (ex-China)” (2020).
24. Ji W., et al. “Cross-species transmission of the newly identified coronavirus 2019-nCoV”. Journal of Medical Virology4 (2020): 433-440.
25. Robertson D., et al. “nCoV's relationship to bat coronavirus and recombination signals no snakes (2020).
26. Xiao K., et al. “Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins”. Nature 7815 (2020): 286-289.
27. Guan W-j., et al. “Clinical Characteristics of Coronavirus Disease 2019 in China”. The New England Journal of Medicine18 (2020): 1708-1720.
28. Li Q., et al. “Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia”. The New England Journal of Medicine13 (2020): 1199-1207.
29. World Health Organization. “WHO experts to travel to China” (2020).

Citation

Citation: Silvere D Zaongo and Dieudonne Ouattara. “COVID-19: The Origin". Acta Scientific Pharmaceutical Sciences 6.1 (2022): 15-17.

Copyright

Copyright: © 2022 Silvere D Zaongo and Dieudonne Ouattara. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.